Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Key facts

Where
Cornebarrieu, Le Coudray, Marseille, Nice és Quint Fonsegrives, FranciaországSee the 5 sites
Phase
2. fázis

Where in Franciaország

  • Clinique Les CèdresCornebarrieu, FranciaországNo longer taking part
  • Les Hopitaux De ChartresLe Coudray, FranciaországNo longer taking part
  • Centre Hospitalier Regional De MarseilleMarseille, FranciaországNo longer taking part
  • Centre Hospitalier Universitaire de NiceNice, FranciaországNo longer taking part
  • Clinique Croix du SudQuint Fonsegrives, FranciaországNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre Hospitalier Universitaire De Nice
Trial code
EU 2022-501133-23-00
Record updated
2025. február 5.
Original description
To Study the effectiveness of high-throughput oxygen therapy on migraine attacks in emergency departments.Read full original descriptionShow less

To Study the effectiveness of high-throughput oxygen therapy on migraine attacks in emergency departments.

Inclusion: Patients 18 years of age or older; Admitted to the emergency department for migraine-evocative headache according to the criteria of the International Classification of Headaches 3rd edition ICHD-3; Written consent to participate after being informed of the study; Pain intensity at least equal to 6 assessed by the patient’s verbal pain self-assessment.

Exclusion: Patients treated with triptan in the last 2 weeks; Patients who consumed NSAIDs in the hour prior to physician review; History of treatment with amiodarone, bleomycin or nitrofurantoin; Patients with risk of respiratory failure by hypercapnia (COPD, cystic fibrosis, morbid obesity, malformation of the chest wall, neuromuscular disorder); History of paraquat poisoning; Patients under legal protection; Disabling migraine crisis during for more than 72 hours.

EU CTIS 2022-501133-23-00